Navigation Links
Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results

continues to pursue

development of SNS-595 in acute myeloid leukemia (AML). A Phase 1b

clinical trial of SNS-595 in combination with cytarabine in relapsed

or refractory AML patients is in progress. Sunesis plans to begin

enrollment in a Phase 2 clinical trial of SNS-595 on a weekly dose

schedule in previously untreated elderly AML patients in the first

half of 2008. Sunesis expects to report data later this year for

both AML clinical trials.

-- Results from a non-clinical study of SNS-032, a potent and selective

inhibitor of cyclin-dependent kinases (CDKs) 2, 7 and 9, were presented

at ASH. These data demonstrated that SNS-032 induces apoptosis in

chronic lymphocytic leukemia (CLL) cells. Furthermore, SNS-032's in

vitro activity compared favorably with flavopiridol in CLL cells

obtained from patients. SNS-032 currently is in a Phase 1 clinical

trial of patients with relapsed or refractory CLL or multiple myeloma.

To date, the drug has been well tolerated in this trial, and dose

escalation in both indications is expected to be completed this year.

-- Sunesis is continuing enrollment in its Phase 1 dose-escalating trial

of SNS-314, a potent and selective inhibitor of Aurora kinases A, B and

C, in advanced solid tumors. To date, SNS-314 has been well tolerated

and no dose-limiting toxicities have been observed. The company

expects to identify a maximum-tolerated dose in this Phase 1 clinical

trial this year.

-- In December, Sunesis and the Multiple Myeloma Research Consortium

(MMRC) announced a collaboration to evaluate the preclinical activity

of SNS-032 in multiple myeloma-relevant models and in primary disease

tissue, extending non-clinical studies performed by Sunesis.

-- In February 2008, Sunesis received

SOURCE Sunesis Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
2. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
3. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
4. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
5. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
6. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
7. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
8. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
9. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 2008
11. Jazz Pharmaceuticals, Inc. Announces Webcast of March 13 Investor Meeting
Post Your Comments:
(Date:7/30/2014)... 30, 2014   Wyle has been ... Lifecycle Mission Support Services (FILMSS) contract awarded by ... the terms of the contract, Wyle will provide ... Field, Calif. In particular, Wyle will provide program ... projects on the International Space Station and collaborative ...
(Date:7/30/2014)... 30, 2014 Yuma Regional Cancer ... complementary therapies brings comprehensive cancer care to Yuma, ... Regional Cancer Center has officially opened. A Mayo ... includes services such as open, semi-private and private ... Cancer Society Resource Center, hematology, rehabilitation center, a ...
(Date:7/30/2014)... July 30, 2014  AtheroNova Inc. (OTCBB: AHRO), ... development of compounds to safely regress atherosclerotic plaque ... that its partner, CardioNova, has accomplished first dosing ... with AtheroNova,s lead compound, AHRO-001.  This Phase 1b ... Phase 1 safety trial completed in February 2014, ...
(Date:7/30/2014)... Adding to their already extensive selection of ... – Buy 2 of any Weighing Boats or Dishes ... technicians looking for durable and reliable weighing products to ... applications including weighing liquids, solid, or granulated samples. ... hexagonal, square, aluminum weighing, and standard boats. Aluminum weighing ...
Breaking Biology Technology:Wyle Wins NASA's Fully Integrated Lifecycle Mission Support Services Contract 2Sate-of-the-Art Yuma Regional Cancer Center Officially Opens 2AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 2AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 3AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 4Weighing Boat Promotion Now Available at, Major Pipette Distributor 2
... March 23, 2011 Advanced Cell Technology, Inc. ("ACT"; ... in the field of regenerative medicine, announced today that ... Company,s patent application to provide broad intellectual property protection ... retinal pigment epithelial (RPE) cells from human embryonic stem ...
... of survival tend to favor the strongest, but University ... world of self-healing materials, it is the somewhat frail ... Langmuir a new model laying out the ... particles that can regenerate after taking damage and are ...
... NEOG ) announced today that its net income ... 28, increased 27% from the previous year to $4,943,000 — ... $0.17 per share. Third quarter revenues increased ... company, compared to the prior year,s $33,833,000. Year to date, ...
Cached Biology Technology:ACT to Be Issued Broad Patent for Human ES Cell-derived RPE Cells in China 2ACT to Be Issued Broad Patent for Human ES Cell-derived RPE Cells in China 3Only the weak survive?: Pitt team adds more give for stronger self-healing materials 2Neogen Reports 27% Increase in Quarterly Net Income 2Neogen Reports 27% Increase in Quarterly Net Income 3Neogen Reports 27% Increase in Quarterly Net Income 4Neogen Reports 27% Increase in Quarterly Net Income 5Neogen Reports 27% Increase in Quarterly Net Income 6
(Date:7/30/2014)... Antonio Life Sciences Institute (SALSI), a joint venture between ... The University of Texas Health Science Center at San ... Pilot Program. The winners, Emily Boice from UTSA and ... $25,000 for their project titled, "Novel engineered ferritins for ... , Boice and Huang,s research is focused on finding ...
(Date:7/30/2014)... baboons suggests that the route to a higher rank is ... of supportive sisters. , A female baboon,s social status is ... of her mother - the higher the mother is ranked, ... rank in female baboons is thought to be determined at ... spot in the pecking order, whereas females born to low-ranking ...
(Date:7/30/2014)... University associate professor Andrew S. Mount, performed cutting-edge research ... for novel anti-fouling paint for ships and boats and ... The team,s findings, published in Nature Communications ... that attaches to a wide variety of surfaces using ... an underwater heavy-duty adhesive. , "In previous research, we ...
Breaking Biology News(10 mins):Supportive moms and sisters boost female baboon's rank 2Supportive moms and sisters boost female baboon's rank 3Study: Marine pest provides advances in maritime anti-fouling and biomedicine 2
... PHILADELPHIA The second American Association for Cancer ... Research: From the Laboratory to the Clinic provides attendees ... in a variety of fields, including the tumor microenvironment, ... takes place March 7-10, 2010, at the King Hussein ...
... of America is pleased to announce the 2010 Yeast ... at the University of British Columbia (UBC) in Vancouver, ... various aspects of eukaryotic biology in yeast. Program ... Canadian astronaut who is also a Member of Parliament. ...
... Texas Imagine a mosquito-borne virus that has already infected ... Asia, the islands of the Indian Ocean, Africa and northern ... that can linger for months or even years. It,s capable ... much of North America. And no vaccine or treatment exists ...
Cached Biology News:The AACR to host second cancer research conference in Jordan 22010 Yeast Genetics and Molecular Biology Meeting 22010 Yeast Genetics and Molecular Biology Meeting 3Experimental vaccine protects monkeys against chikungunya 2
poliovirus receptor-related 2 (herpesvirus entry mediator B), mRNA...
... consists of AmnioMAX-C100 Basal ... and AmnioMAX-C100 Supplement (Cat. ... complete with antibiotics and ... requires no further supplementation ...
Immunogen: Recombinant full length protein, corresponding to amino acids 1-435 of Human AP2M1. Storage: -20 C, Avoid Freeze/Thaw Cycles...
... Rabbit polyclonal to Parathyroid Hormone Receptor ... tested applications). Antigen: ... extracellular amino acids 99-116 of Human ... Entrez Gene ID: 5746 ...
Biology Products: